Ngeunaan Dokter
Dr Benjamin Levy mangrupakeun onkologi médis thoracic anu ogé boga fungsi minangka diréktur klinis onkologi médis pikeun Johns Hopkins Sidney Kimmel Kangker Center di Rumah Sakit Peringatan Sibley sarta salaku profesor gaul onkologi di Johns Hopkins University School of Medicine. Anjeunna damel di Rumah Sakit Peringatan Sibley Johns Hopkins Sidney Kimmel Cancer Center.
Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced kanker paru, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and kanker sirah sareng beuheung.
Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his kanker prostat clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Percobaan klinis Kantor.
Dr Levy parantos ngalayanan seueur panitia Amérika Society of Clinical Oncology (ASCO) sareng ayeuna mangrupikeun redaktur gaul pikeun Komite Universitas ASCO. Anjeunna ngajabat dina dewan redaksi Journal of Clinical Oncology salami dua taun sareng ayeuna mangrupikeun pamariksaan ad hoc pikeun publikasi tambahan sapertos Kanker Lung klinis, The Oncologist, sareng target Onco. Dr Levy nembe dipilih salaku salah sahiji ngan 15 onkologi di nagara éta pikeun ilubiung dina program Pangwangunan Kapamingpinan ASCO bergengsi, nu boga tujuan pikeun manggihan tur ngalatih pamingpin ASCO hareup. Dr Levy ogé ngajabat dina Komite Pernafasan ALLIANCE, Komite Pementasan IASLC, sareng Komite Pangembangan Karir & Fellowship IASLC salian kagiatan ASCO na.
rumah sakit
Spésialisasi
Prosedur Dilaksanakeun
- kanker paru
- immunotherapy
Panilitian & Publikasi
Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Lewi BP. "Survival of Asian Awéwé Jeung Kanker Lung Advanced dina Era of Tyrosine Kinase Inhibitor Therapy." Kangker Lung Clin. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008.
Lewi BP, Rao P, Becker DJ, Becker K. "Narajang Target Pindah: Ngartos Résistansi sareng Ngatur Kamajuan di Pasén Kanker Paru-Paru EGFR-positip Diperlakukeun Kalayan Inhibitor Tirosin Kinase." Onkologi (Williston Park). 2016 Jul;30 (7): 601-12. Tinjauan.
Lewi BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. "Uji Molekul pikeun Pangobatan Kanker Paru-paru Sél Non-Leutik Métastatik: Kumaha Nerapkeun Rekomendasi Berbasis Bukti." Oncologist. 2015 Oktober;20(10):1175-81. doi: 10.1634 / theoncologist.2015-0114.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Lewi BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS . "Kagiatan sareng kasalametan nivolumab, inhibitor pamariksaan imun anti-PD-1, pikeun penderita kanker paru-paru non-sél leutik anu maju, refractory (CheckMate 063): fase 2, percobaan panangan tunggal." Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.
Lewi BP, Becker DJ. "Waktu pikeun screening tomography diitung dosis rendah ayeuna: sudut pandang onkologi médis." Onkologi (Williston Park). 2014 Nov;28(11):964-6. Taya abstrak sadia.
